非选择性β受体阻滞剂预防静脉曲张出血及再出血

肝脏 ›› 2023, Vol. 28 ›› Issue (1): 117-120.

非选择性β受体阻滞剂预防静脉曲张出血及再出血

章正兰, 莫瑞东, 姜绍文, 谢青

200025 上海交通大学医学院附属瑞金医院感染科

收稿日期:2022-05-17 出版日期:2023-01-31 发布日期:2023-02-21
通讯作者: 姜绍文,Email:jiang1989111@126.com
基金资助:
上海市临床重点专科(感染病学)(shslczdzk01103)、国家自然科学基金(81770587,82070604,82000588)、十三五“科技部重大专项”(2017ZX10203201-008, 2018ZX09201016-003-001, 2017ZX10202202-005-004)

Received:2022-05-17 Online:2023-01-31 Published:2023-02-21

摘要/Abstract

摘要： 胃食管静脉曲张出血是肝硬化失代偿期常见的并发症,出血后 1年内再出血率高达60％,门静脉压力升高是食管胃底静脉破裂出血的主要原因。非选择性β受体阻滞剂(NSBB)通过阻断β肾上腺素能受体降低门静脉压力,从而达到降低静脉曲张出血的风险,目前已成为胃食管静脉曲张出血一级和二级预防的首选药物, 以HVPG指导的NSBB治疗和预防门静脉高压症患者首次和复发静脉曲张出血的个体化方案已引起临床关注,本文将结合最新的研究结果,探讨NSBB预防静脉曲张出血及再出血的个体化治疗。

关键词: 非选择性β受体阻滞剂, 肝硬化, 门脉高压, 胃食管静脉曲张出血, 个体化方案

章正兰, 莫瑞东, 姜绍文, 谢青. 非选择性β受体阻滞剂预防静脉曲张出血及再出血[J]. 肝脏, 2023, 28(1): 117-120.

参考文献

[1] Reiberger T, Schwabl P, Trauner M, et al. Measurement of the hepatic venous pressure gradient and transjugular liver biopsy. J Vis Exp, 2020, (160).
[2] Groszmann RJ, Garcia-T sao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med, 2005, 353(21):2254-2261.
[3] 赵庆美,韩秀敏. β受体阻滞剂治疗食管静脉曲张破裂出血患者的临床效果. 国际医药卫生导报, 2021, 27(17):2764-2766.
[4] Iwakiri Y. Pathophysiology of portal hypertension. Portal Hypertens, 2014, 18(2):281-291.
[5] Reverter E, Tandon P, Augustin S, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology, 2014, 146(2):412-419.e3.
[6] Poynard T, Cale's P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med, 1991, 324(22):1532-1538.
[7] Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology, 1990, 99(5):1401-1407.
[8] de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension:report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol, 2015, 63(3):743-752.
[9] Angeli P, Bernardi M, Villanueva C, et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol, 2018,69(2):406-460.
[10] Groszmann RJ, Garcia-T sao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med, 2005, 353(21):2254-2261.
[11] Villanueva C, Albillos A, Genesca J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI):a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2019, 393(10181):1597-1608.
[12] Jachs M, Reiberger T. Prevention of variceal bleeding and rebleeding by Nonselective Beta-Blockers: A tailored approach. Clin Liver Dis, 2021, 25(2):311-326.
[13] Kalambokis GN, Christodoulou D, Baltayiannis G, et al. Propranolol use beyond 6 months increases mortality in patients with Child-Pugh C cirrhosis and ascites:correspondence. Hepatology, 2016, 64(5):1806-1808.
[14] Sharma M, Singh S, Desai V et al. Comparison of therapies for primary prevention of esophageal variceal bleeding: a systematic review and network meta-analysis. Hepatology, 2019, 69(4):1657-1675.
[15] Lo G-H. Letter to the editor: beta-blockers are preferable to banding ligation for primary prophylaxis of variceal bleeding? Hepatology, 2019, 70(5):1876.
[16] Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut, 2013, 62(11):1634-1641.
[17] Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology, 2009, 50(3):825-833.
[18] Stanley AJ, Dickson S, Hayes PC, et al. Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding. J Hepatol, 2014, 61(5):1014-1019.
[19] Puente A, Herna ndez-Gea V, Graupera I, et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review. Liver Int, 2014, 34(6):823-833.
[20] Téllez L, Ibáez-Samaniego L, Pérez del Villar C, et al. Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. J Hepatol, 2020, 73:1404-1414.
[21] Chirapongsathorn S, Valentin N, Alahdab F, et al. Nonselective b-blockers and survival in patients with cirrhosis and ascites: a systematic review and meta-analysis. Clin Gastroenterol Hepatol, 2016, 14(8):1096-10104.e9.
[22] Turco L, Villanueva C, La Mura V, et al. Lowering portal pressure improves outcomes of patients with cirrhosis, with or without ascites: a meta-analysis. Clin Gastroenterol Hepatol, 2020, 18(2):313-327.e6.
[23] Mookerjee RP, Pavesi M, Thomsen KL, et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol, 2016, 64(3):574-582.